



### Audit activity to date by practice



- Practices active
- Practices complete with data
- Practices complete pending data
- Practices scheduled
- Practices cancelled

Number of individual GP practices with review activity	73
Number of unique CCGs / Healthboards with review	3
Number of individual practices in aggregate dataset	71
Combined registered population of aggregate dataset	586,796

### Executive summary of aggregate data :28,657 patients (total population = 586,796 patients)




<b>42%</b> patients with OP taking BSA	<b>5.0</b> average duration of treatment of currently prescribed BSA (years)
<b>6,942</b> patients at high or intermediate risk of fracture, OP and no BSA (1a)	<b>3,142</b> patients with long term BSA treatment (2a)
<b>4,009</b> patient at high risk of fracture, no OP and no BSA (1b)	<b>3,990</b> incidence of low adherence, clinical issues or possible treatment failure in current BSA use

*BSA = bone sparing agent OP = Osteoporosis*      *\* patients with BSA prescribed and at least one supply in last 12 months*


### Analysis of fracture risk assessment (FRAX) in identified patients




### Analysis of bone sparing agent treatment in high risk patient groups



### Analysis of patients with a recorded diagnosis of osteoporosis




### Analysis of osteoporosis treatment history with respect to cumulative number of osteoporosis markers\*



\*osteoporosis markers list (1 point for each):


current BSA, H/O BSA, coded DXA, DXA confirms OP, H/O fracture, glucocorticoid, FRAX = treat

### Number of previous BSA used in cohort 1a patients with osteoporosis not currently receiving BSA




Never prescribed BSA History of 1 BSA History of 2 BSA History of ≥ 3 BSA


### Combined duration of all previous BSA therapy in patients with osteoporosis not currently receiving BSA




### Analysis of patients currently taking a bone sparing therapy






### Analysis of current bone sparing agent across population




### Analysis of current bone sparing agent prescribing across aggregated practices







Duration of BSA treatment in cohort 2a patients (patients receiving current bone sparing therapy duration above 3 years (zoledronate) or 5 years (other therapies))




Indication to continue BSA therapy amongst cohort 2a population




Analysis of incidence of low adherence, clinical issues or possible treatment failure in current BSA use



Analysis of fragility fractures recorded as a proportion of all 'fragility type' fractures sustained since April 2012 with respect to age



Proportion of patients over 50 sustaining a fragility type fracture since April 2012 with a coded fragility fracture



■ Coded fragility fracture n = 4188  
 ■ Not coded fragility fracture n = 4908

Analysis of osteoporosis QOF achievement and potential for improvement

